NASDAQ$IMCR
Immunocore Holdings plc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Immunocore reported Q4 2023 financial results, highlighted by KIMMTRAK net revenues of $67.6 million and progress in clinical trials and collaborations.
Immunocore reported Q4 2023 financial results with KIMMTRAK net revenues reaching $67.6 million and a net loss of $19.7 million. The company is advancing its clinical trials, including a collaboration with Bristol Myers Squibb. Cash and cash equivalents stood at $442.6 million as of December 31, 2023, with additional funds raised in February 2024.
- KIMMTRAK net revenues reached $67.6 million in Q4 2023 and $238.7 million for the full year 2023.
- Clinical trial collaboration and supply agreement established with Bristol Myers Squibb for IMC-F106C with nivolumab.
- Multiple clinical readouts for IMC-F106C from Phase 1/2 trial expected to start in Q2 2024.
- Cash and cash equivalents totaled $442.6 million as of December 31, 2023, with $389.3 million net proceeds from a February 2024 Convertible Senior Notes offering.
Headline financials
Revenue & EPS history
Immunocore · Revenue · Quarterly
$70.8M
Forward guidance
Immunocore is focused on expanding the reach of KIMMTRAK, advancing its PRAME ImmTAC therapy, and progressing its clinical candidates across oncology, infectious diseases, and autoimmune diseases.
Tailwinds
- Maximizing the potential of KIMMTRAK.
- Launching PRAME ImmTAC therapy.
- Advancing clinical candidates across oncology.
- Expanding into infectious diseases.
- Entering autoimmune diseases.
Headwinds
- Impact of worsening macroeconomic conditions.
- Ability to obtain clinical and commercial supply.
- Obtaining and maintaining regulatory approval.
- Competition with respect to market opportunities.
- Unexpected safety or efficacy data.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-0.3%
Avg return
Earnings day
+0.9%
Avg return
5 days after
-1.2%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+8.3%
Q3 2023
Best reaction
-11.0%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.6% | +0.0% | -2.1% | |
| Q4 2025 | -4.8% | -3.0% | -12.6% | |
| Q3 2025 | -3.2% | +9.7% | +21.5% | |
| Q1 2025 | +6.3% | +5.3% | +32.8% | |
| Q4 2024 | +5.3% | -1.1% | +1.3% | |
| Q3 2024 | +4.0% | +5.0% | -4.5% | |
| Q2 2024 | +0.8% | +1.7% | -9.5% | |
| Q1 2024 | -1.9% | -6.6% | -31.7% | |
| Q4 2023 | -4.6% | -7.2% | -7.7% | |
| Q3 2023 | +8.3% | +4.6% | +15.8% | |
| Q2 2023 | -3.3% | -5.9% | -12.7% | |
| Q1 2023 | -1.5% | +3.2% | -4.6% | |
| Q4 2022 | -4.9% | -5.1% | -9.9% | |
| Q3 2022 | +2.9% | +13.7% | +9.3% | |
| Q2 2022 | +1.6% | +5.8% | -13.5% | |
| Q1 2022 | -11.0% | +2.7% | +1.4% | |
| Q4 2021 | -0.7% | +7.5% | +37.7% | |
| Q3 2021 | +0.4% | -0.2% | -21.3% | |
| Q2 2021 | -4.9% | -9.5% | -1.4% | |
| Q1 2021 | -1.5% | -9.4% | -5.3% | |
| Q4 2020 | +0.1% | +6.8% | -7.1% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro